3 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Withdrawn 3 |
Follow Schizoaffective Disorder: new trials by email Literature Review of Schizoaffective Disorder trials Research Report on Schizoaffective Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder LYN-005 (risperidone), Placebo for LYN-005, IR Risperidone - Schizophrenia, Schizoaffective Disorder | Phase 3 | Withdrawn | Lyndra Inc. | 2025-04-18 | 2025-04-08 | |
| Zyprexa and Task Engagement in Schizophrenia Olanzapine (Zyprexa), Typicals - Schizophrenia, Schizoaffective Disorder | Phase 3 | Withdrawn | VA Connecticut Healthcare System | 2007-02-01 | 2013-12-23 | |
| Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients Bexarotene, Fenretinide, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 3 | Withdrawn | Beersheva Mental Health Center | 2010-06-29 |
Psychotic Disorders (3) · Schizophrenia (3)
Mental Disorders (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3)
Bexarotene (1) · Fenretinide (1) · Olanzapine (1) · Risperidone (1)
Beersheva Mental Health Center (1) · Lyndra Inc. (1) · VA Connecticut Healthcare System (1)
Israel (1) · United States (1)
Chanoch Miodownik, MD (1) · Jimmy Choi, Psy.D. (1) · Nayana Nagaraj (1) · Vladimir Lerner, MD, PhD (1)